CHMP

Stamp of approval
#CHMP #EMA #European Medicines Agency #European Union #Marketing approval authorisation

EU’s CHMP supports 14 new medicines, but rejects lecanemab

The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) recommended 14 medicines for approval at its July 2024 meeting. However, the CHMP recommended not granting a marketing authorisation for Leqembi (lecanemab) for the treatment of Alzheimer’s disease. The committee said that the observed effect of Leqembi… Read More

#News #Regulatory #Trending News

Bladder
#Bladder cancer #CHMP #Genetics / genomics #Janssen #Oncology

CHMP okays first therapy targeting FGFR3 alterations in bladder cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Janssen-Cilag’s Balversa (erdafitinib). It is recommended as a monotherapy to treat adult patients with unresectable or metastatic urothelial carcinoma, harbouring susceptible FGFR3 genetic alterations who have previously received at… Read More

#News #Regulatory

#Allergy #CHMP #FDA #Melanoma #Regulatory #Schizophrenia #Scleroderma

This week in drug discovery (26 Feb – 1 March) 

News round-up for 26 Feb – 1 March by DDW Digital Content Editor Diana Spencer. The news highlights this week all focus on regulatory decisions, both positive and negative. The first therapy was approved for allergic reactions to food, a drug for scleroderma secured Fast Track Designation, and… Read More

#News

CAR-T therapy
#CAR-T #Cell therapy #CHMP #European Medicines Agency #Myeloma #Oncology

CAR-T therapy recommended for melanoma after first relapse

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of a Type II variation for Carvykti (ciltacabtagene autoleucel; cilta-cel) for the earlier treatment of relapsed and refractory multiple myeloma (RRMM). The recommended indication for cilta-cel is for the treatment of… Read More

#News #Regulatory

The European Medicines Agency building
#CHMP #EU #European Medicines Agency #Gene therapy #Regulatory

New drug recommendations by the EU’s CHMP

The European Medicines Agency (EMA) human medicines committee (CHMP) made a number of key recommendations at its December 2023 meeting. Casgevy The committee recommended granting a conditional marketing authorisation for Casgevy (exagamglogene autotemcel), an advanced therapy medicinal product (ATMP) for the treatment of transfusion dependent beta-thalassemia and severe sickle cell… Read More

#News #Regulatory #Trending News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

DDW Highlights: 7 August 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The pace of innovation in cancer drug discovery showed no signs of slowing… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (31 July – 4 August)  

News round-up for 31 July – 4 August by DDW Digital Content Editor Diana Spencer. The pace of innovation in cancer drug discovery showed no signs of slowing this week, with several pretty momentous discoveries boosting research in the sector. These include the creation of a… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

New podcast episode: DDW Highlights 31 July 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  To coincide with the publication of the DDW eBook ‘Antibody discovery:… Read More

#News

#Antibodies #Bispecific Antibodies #Cancer research #CHMP #Oncology

This week in drug discovery (24-28 July)  

News round-up for 24-28 July by DDW Digital Content Editor Diana Spencer. To coincide with the publication of the DDW eBook ‘Antibody discovery: Breakthroughs accelerating therapeutic antibodies’, our news highlights this week all focus on antibodies, particularly the recommendation by the EU’s CHMP… Read More

#News

Leukaemia
#Blood cancer #Cancer research #CHMP #EMA #European Commission #Jazz Pharmaceuticals #Leukaemia #Oncology

EU positive opinion for acute lymphoblastic leukaemia drug

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authorisation of JZP458 (a recombinant Erwinia asparaginase or crisantaspase). It has been recommended for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic… Read More

#News #Regulatory

Bispecific antibodies
#AbbVie #Bispecific Antibodies #Cancer research #CHMP #EMA #Genmab #Haematology #Oncology

Bispecific antibody a “promising treatment option” for DLBCL

The EU Committee for Medicinal Products for Human Use (CHMP) has recommended the granting of conditional marketing authorisation for epcoritamab (Tepkinly) as a monotherapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The final… Read More

#News #Regulatory

Multiple myeloma
#Bispecific Antibodies #Cancer research #CHMP #EMA #Janssen #Myeloma #Oncology

CHMP recommendation for bispecific antibody talquetamab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The drug has received a positive opinion for use as a monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who… Read More

#News #Regulatory

Stamp of approval
#CHMP #EMA #Marketing approval authorisation #Regulatory

The CHMP recommends 14 new medicines for approval

The EU’s Committee for Medicinal Products for Human Use (CHMP) recommended granting a marketing authorisation for 14 new medicines in its July meeting. The following novel medicines and biosimilars each received a positive opinion: Abrysvo (bivalent, recombinant), a vaccine to protect small infants and older people against lower respiratory tract… Read More

#News #Regulatory

Male patient with doctor
#Cancer research #CHMP #European Medicines Agency #Gene mutation #Oncology #Phase III trial #Prostate cancer

Prostate cancer combination therapy reduces risk of death

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.  Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by the Committee for… Read More

#News #Regulatory

Woman bleeding from the nose
#CHMP #CSL #Europe #European Commission #Haemophilia #Marketing approval authorisation

EU-approved gene therapy reduced haemophilia bleeds by 64%

The European Commission has granted conditional marketing authorisation for CSL’s Hemgenix (etranacogene dezaparvovec), the first one-time gene therapy for severe and moderately severe haemophilia B (congenital Factor IX deficiency) in adults without a history of Factor IX inhibitors.   In an ongoing clinical trial, the drug reduced the… Read More

#Editor's Choice #News

Plaque psoriasis
#Bristol Myers Squibb #CHMP #Dermatology #European Medicines Agency #Phase III trial

First oral allosteric TYK2 inhibitor recommended in EU

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended the approval of Sotyktu (deucravacitinib) for the treatment of adults with moderate-to-severe plaque psoriasis.   Sotyktu, an oral medication taken once-daily, is a first-in-class, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment… Read More

#News #Regulatory